A dose-escalation, dose-extension and efficacy-extension, phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of AP-L1898 capsule for the treatment of the patients with locally advanced or metastatic non-small cell lung cancer

NCT ID NCT04993391

NEW Sponsor: Suzhou Junjing BioSciences Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Sep 10, 2026 · Last updated Sep 10, 2026

Summary

This is a phase I/II, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, PK profile and efficacy of JS111 for patients with Non-small cell lung cance. This study is divided into 3 periods: dose escalation stage, dose extension stage, and efficacy extension stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

32 people

The number who actually took part.

Started

Jul 2021

Finished

Feb 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

"Inclusion criteria: 1. Age≥18 years, male or female; 2. Patients with histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) or metastatic (stage IV) NSCLC that can not undergo radical chemoradiotherapy; 3. Dose-escalation and dose-extension periods: failure of standard of care or intolerance of standard of care, having received at least one or more systemic therapeutic regimens for locally advanced or metastatic disease; 4. There is clear evidence showing carrying EGFR exon 20 insertion and other rare EGFR mutations (only applicable for dose-extension and efficacy-extension periods). The test method can use: ARMS method for tissue or cell specimen (need to be tested in national certified laboratory), NGS method for tissue or blood specimen (need to be tested in CLIA or CAP certified laboratory). Note: enrollment of patients does not need to be confirmed by central laboratory; 5. At least one measurable lesion meeting RECIST v1.1 definition, no history of puncture biopsy for the target lesion within the previous two weeks; 6. United States Eastern Cooperative Oncology Group (ECOG) Performance Status score 0\~1; 7. Life expectancy \>12 weeks; 8. Having adequate function of important organs at screening (requiring no blood transfusion, no use of hematopoietic stimulating factor or human albumin preparation within 14 days prior to screening): 1. Absolute neutrophil count (ANC) ≥1.5x109/L; 2. Platelets ≥100×109/L; 3. Haemoglobin \> 90 g/L; 4. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5×upper limit of normal (ULN) (for known liver metastasis, ≤ 5×ULN); 5. Total bilirubin ≤1.5×ULN; 6. Coagulation function INR≤1.5 ULN; 7. Serum creatinine ≤ 1.5×ULN or creatinine clearance (Ccr, calculated using Cockcroft-Gault formula) ≥45 mL/min; 8. Serum lipase and amylase ≤ 1.5 × ULN; 9. Serum pregnancy test must be confirmed as negative for women of childbearing potential within 7 days prior to enrollment, who agree upon use of effective contraceptive measures during use of the study drug and within 6 months after the last dose. Women of childbearing potential in this protocol is defined as sexually mature women: 1) no hysterectomy or bilateral ovariectomy, 2) uncontinuous natural menopause for 24 months (i.e., menses occurred at any time in the previous consecutive 24 months; fertility can not be excluded in case of amenorrhoea following cancer therapy). Male subjects whose partners are women of childbearing potential must agree to take effective contraceptive measures during the use of study drug and within 6 months after the last dose; 10. Being voluntary to participate in this study after sufficient informed consent and sign the informed consent form. Exclusion criteria: 1. Use of any chemotherapeutic agen within 14 days prior to the first dose of AP-L1898; or the time from discontinuation of other investigational product to the use of anticancer drug less than 5 half-lives or 28 days, whichever is shorter; 2. EGFR exon 20 insertion cohort in efficacy-extension stage: once used the drugs targeting EGFR exon 20 insertion mutation (e.g., AZD9291, TAK-788, Poziotinib, CLN-081, JNJ-372, etc.); the patients previously receiving AZD9291 for treatment of EGFR sensitive mutation are allowed to be enrolled; 3. Ongoing use of CYP3A potent inhibitor or inducer, or discontinuation of potent inhibitor less than 5 half-lives of the drug, or discontinuation of potent inducer less than 5 half-lives of the drug or 14 days (whichever is longer) at the first dose of AP-L1898; 4. Not recovered from the adverse event induced by previous antitumor therapy at screening (recovered to ≤ grade 1) (except alopecia); 5. Having other malignant tumors within 5 years prior to the start of treatment or simultaneously (except radically treated non-melanoma without evidence on recurrence of disease, including skin basal cell carcinoma or squamous cell carcinoma, breast/cervical carcinoma in situ, superficial bladder cancer and other carcinomas in situ); 6. Presence of active gastrointestinal disease or other conditions that may obviously affect absorption, metabolism or excretion of drugs; 7. Patients who known to have received organ transplantation; 8. Major surgery performed within 28 days prior to the first dose. Small surgery permitted, e.g., minimally invasive biopsy; 9. Patents with carcinomatous meningitis, spinal cord compression at present; 10. At rested state, mean corrected QT interval QTc, using Fridericia's correction formula\>450 ms in man or \>470 ms in woman on electrocardiography (ECG) (repeated for three times). A variety of clinically significant abnormalities in cardiac rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, degree III heart block, degree II heart block, PR interval\>250 ms. Any factors that may increase the risk of prolonged QTc interval or risk of arrhythmic events, e.g., heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in lineal relatives, or ongoing use of any drug known to prolong QT interval; 11. History of poorly controlled hypertension; 12. Previous history of the following diseases: interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, active interstitial lung disease with clinical evidence; 13. Patients with active brain metastasis, if the CNS metastasis is only limited to supratentorial area or cerebellum that has been adequately treated (surgery or radiotherapy) and radiologically stable for at least 4 weeks, and no corticosteroid is needed to control symptoms, the patients will be allowed to be enrolled; 14. In acute infection phase and requiring pharmacotherapy; 15. HBV DNA≥103 copies/mL or ≥200 IU/mL when the hepatitis B surface antigen is positive or hepatitis B core antibody is positive; 16. HCV-RNA \> the upper limit of reference at the site when hepatitis C antibody is positive; 17. Human immunodeficiency virus (HIV) antibody positive; 18. Patient with a previous history of clear mental disorder and taking drugs for treatment; 19. Patient with a history of drug abuse or drug taking; 20. Pregnant or lactating women; 21. Presence of other factors that may possibly affect the study results, interfere with their participation in the entire study, including previous or current physical condition (e.g., ocular disease, including corneal ulcer, conjunctivitis, etc.), treatment or laboratory examination abnormality, unwillingness to comply with each procedure, restriction and requirement in the study, as considered by investigators. A limited list of criteria for selection of participants in the clinical study, provided in terms of inclusion and exclusion criteria and suitable for assisting potential participants in identifying clinical studies of interest. Use a bulleted list for each criterion below the headers ""Inclusion Criteria"" and ""Exclusion Criteria"". (Limit: 15,000 characters.)"

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer

Contacts and locations

Locations

Affiliated Hospital of Guangdong Medical University

Zhanjiang, Guangdong, 524023, China
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China
Cancer Hospital Chinese Academy of Medical Sciences，Shenzhen center

Shenzhen, Guangdong, 518116, China
Chinese People's Liberation Army Army Characteristic Medical Center

Chongqing, Chongqing Municipality, 400042, China
Fujian Cancer Hospital

Fuzhou, Fujian, 350001, China
Hangzhou Cancer Hospital

Hangzhou, Zhejiang, 310002, China
Harbin Medical University Cancer Hospital

Haerbin, Heilongjiang, 150081, China
Henan Cancer Hospital

Zhengzhou, Henan, 450008, China
Hubei Cancer Hospital

Wuhan, Hubei, 430079, China
Hunan Cancer Hospital

Changsha, China
Jilin Cancer Hospital

Changchun, Jilin, 130012, China
Liaoning Cancer Hospital

Shenyang, Liaoning, 110042, China
Liuzhou People's Hospital

Liuzhou, Guangxi, 545006, China
North Jiangsu People's Hospital

Yangzhou, Jiangsu, 225001, China
Shandong Cancer Hospital

Jinan, Shandong, 250117, China
Shanghai Oriental Hospital

Shanghai, Shanghai Municipality, 200127, China
Shanghai Pulmonary Hospital

Shanghai, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310016, China
Sun Yat-sen Memorial Hospital ], Sun Yat-sen University

Guangzhou, Guangdong, 510120, China
Taizhou Hospital of Zhejiang Province

Taizhou, Zhejiang, 317000, China
The Affiliated Hospital of Inner Mongolia Medical University

Hohhot, Inner Mongolia, 010050, China
The First Affiliated Hospital , Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China
The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, 510163, China
The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330006, China
The First Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, 710061, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450052, China
The First Hospital of China Medical University

Shenyang, Liaoning, 110001, China
The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310009, China
The Second Xiangya Hospital of Central South University

Changsha, Hunan, 410011, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

Wuhan, Hubei, 430030, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, 430023, China
Weifang People's Hospital

Weifang, Shandong, 261000, China
Xiangya Hospital of Central South University

Changsha, Hunan, 410008, China
Yunnan Cancer Hospital

Kunming, Yunnan, 650106, China
Zhejiang Cancer Hospital

Hangzhou, China
Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.